Literature DB >> 24243633

Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.

Emily Avitan-Hersh1, Sameh Tatur, Margarita Indelman, Vardit Gepstein, Roni Shreter, Dov Hershkovitz, Riva Brick, Reuven Bergman, Dov Tiosano.   

Abstract

INTRODUCTION: Epidermal nevus syndrome is a rare group of disorders characterized by the combination of congenital epidermal nevi and extracutaneous features, including skeletal, neurological, ocular, and other systemic findings. We report a case of keratinocytic epidermal nevus syndrome that includes a thymoma, bone dysplasia, and hypophosphatemia with elevated fibroblast growth factor 23 (FGF23) levels associated with postzygotic HRAS mutation. CASE REPORT: A 14-year-old boy was admitted due to recent limping. The physical examination revealed multiple right-sided linear epidermal nevi along Blaschko's lines. Magnetic resonance imaging showed cystic lesions in cervical bones and thymoma, and x-ray examination showed cystic lesions in the hands. Biochemical studies demonstrated severe hypophosphatemia, normocalcemia, high normal PTH, low 25-hydroxyvitamin D and low 1,25-dihydroxyvitamin D levels. The serum FGF23 C-terminal level was normal, but the intact FGF23 level was found to be elevated. Genetic evaluation revealed a heterozygote mutation in the HRAS gene in both the keratinocytic epidermal nevus and thymoma but not in DNA extracted from blood lymphocytes, thus establishing the mutation as postzygotic. DISCUSSION: Postzygotic mutations in HRAS lead to elevation of FGF23 levels, as found in mutated PHEX, FGF23, DMP1, and ENPP1 genes, which lead to hypophosphatemia.
CONCLUSION: An identical postzygotic HRAS mutation was shown to be present in both keratinocytic epidermal nevus and thymoma and to be associated with bone lesions and hypophosphatemia due to elevated FGF23 levels. These may all be related to the HRAS mutation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24243633     DOI: 10.1210/jc.2013-2813

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  RAS in FGF23: another piece in the puzzle.

Authors:  Diana Ovejero; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-01       Impact factor: 5.958

Review 2.  Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.

Authors:  D Ovejero; Y H Lim; A M Boyce; R I Gafni; E McCarthy; T A Nguyen; L F Eichenfield; C M C DeKlotz; L C Guthrie; L L Tosi; P S Thornton; K A Choate; M T Collins
Journal:  Osteoporos Int       Date:  2016-08-06       Impact factor: 4.507

3.  Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23.

Authors:  Xiaobin Han; Zhousheng Xiao; L Darryl Quarles
Journal:  J Biol Chem       Date:  2015-03-09       Impact factor: 5.157

4.  Keratinocytic epidermal nevus syndrome with Schwann cell proliferation, lipomatous tumour and mosaic KRAS mutation.

Authors:  Said Farschtschi; Victor-Felix Mautner; Silke Hollants; Christian Hagel; Marijke Spaepen; Christoph Schulte; Eric Legius; Hilde Brems
Journal:  BMC Med Genet       Date:  2015-02-10       Impact factor: 2.103

Review 5.  Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?

Authors:  Adriana C H van Engen-van Grunsven; Heidi Kusters-Vandevelde; Patricia J T A Groenen; Willeke A M Blokx
Journal:  Front Med (Lausanne)       Date:  2014-10-31

Review 6.  The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine.

Authors:  Niek F Dirks; Mariëtte T Ackermans; Paul Lips; Renate T de Jongh; Marc G Vervloet; Robert de Jonge; Annemieke C Heijboer
Journal:  Nutrients       Date:  2018-04-13       Impact factor: 5.717

7.  Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption.

Authors:  Naoko Hidaka; Hajime Kato; Minae Koga; Masaki Katsura; Yuko Oyama; Yuka Kinoshita; Seiji Fukumoto; Noriko Makita; Masaomi Nangaku; Nobuaki Ito
Journal:  Bone Rep       Date:  2021-10-16

8.  Identified the Synergistic Mechanism of Drynariae Rhizoma for Treating Fracture Based on Network Pharmacology.

Authors:  Haixiong Lin; Xiaotong Wang; Ligang Wang; Hang Dong; Peizhen Huang; Qunbin Cai; Yingjie Mo; Feng Huang; Ziwei Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-20       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.